Participate in Research
Clinical trials help find new methods for diagnosing, treating, managing, and preventing Crohn's disease and ulcerative colitis. Even the most promising scientific findings must first be proven to be safe and effective in clinical trials before they can be used as standard treatment for inflammatory bowel disease (IBD).
If you are interested in learning more about clinical trials, speak with your doctor.
Active studies recruiting participants:
- The IMAGINE Network-Interaction between inflammation, microbiome, diet and mental health in IBD or IBS patients
Persons from across Canada are being invited to participate in the IMAGINE research study. The IMAGINE Network is investigating the interactions between inflammation, microbiome, diet and mental health in patient with IBD (Crohn’s disease or ulcerative colitis) or irritable bowel syndrome (IBS). IMAGINE is also studying whether new therapies (fecal transplants, diet, probiotics, cognitive behaviour therapy) have the potential to transform the management of IBD and IBS and their associated mental health issues.
You may be eligible to participate in this study if you have been diagnosed by your physician with Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), including ulcerative colitis or Crohn’s disease, or are a healthy individual without gastrointestinal symptoms. Visit www.imaginespor.com
for more information and to find a recruitment site near you.
- Teens and Inflammatory Bowel Disease
The Family Health Lab
at University of Saskatchewan is currently conducting an online study looking at the relationship between emotions and IBD-related symptoms in teens with inflammatory bowel disease (IBD).
Who is eligible to participate?
Teens ages 14-18 who have been diagnosed with ulcerative colitis or Crohn's disease who has a parent that will provide consent for the teen to participate.
To register for the study or for more information, please contact:
Teens and parents able to participate are eligible to enter a draw to win one of three $50 gift cards.
- Peditric Crohn’s Disease Fecal Microbiota Transplant: PediCRaFT Trial
The PedCRaFT (peditric Crohn’s Disease Fecal Microbiota Transplant) Trial is the first Health Canada approved randomized-control fecal transplant study for Pediatric Crohn’s disease in Canada.
i) Colonoscopy-initial baseline colonoscopy under anesthesia, where you will receive an infusion via colonoscopy of either healthy bacteria or a normal saline placebo.
ii) Oral Capsule-2x week for 6 weeks, you will receive pill capsules that may be taken at home. Pill capsules will either contain healthy bacteria or sugar-containing placebo.
We will ask you to provide: 1) Bloodwork 2) Urine Samples 3) Stool samples 4) Complete a 6-Question survey
This study has been approved by the Hamilton Integrated Research Ethics Board.
Who is eligible?
Children between ages 3 to 17 diagnosed with Crohn’s disease or IBD-U favouring Crohn’s disease (as identified by your physician) on a stable therapy (no major changes to medication within the last four weeks).
Principal Investigator: Dr Nikhil Pai, Division of Pediatric GI and Nutrition McMaster Children's Hospital
To participate, contact
Lee Hill, BSc (Med)(Hons), PhD (c) firstname.lastname@example.org
The PediCRaFT Research Team at PediCRaftTrial@gmail.com
- Fecal Microbiota Transplantation (FMT) for Crohn's Disease
The human body contains ten bacterial cells for every human cell. This vast, largely unexplored bacterial community, known as the microbiome, has been linked to gastrointestinal health and disease. In the case of inflammatory bowel disease (IBD), it is thought that the immune system may be responding inappropriately to the microbiome. Therefore, it has been hypothesized that changing the microbiome may be an effective treatment for IBD. One way to accomplish this is using Fecal Microbiota Transplantation (FMT), an innovative investigational treatment that has proven effective in the treatment of C. difficile infection.
The purpose of this study is to determine whether FMT is similarly safe and effective in the treatment of mild-to-moderate Crohn’s disease. During FMT, a fecal preparation from a carefully screened, healthy stool donor is transplanted into the colon of the patient. There are multiple routes of administration. We will use both in this study.
Patients will receive a total of eight FMT/placebo treatments in the study. Patients receiving FMT will be assigned a single donor. The first will be given by colonoscopy at week zero, followed by seven others given by capsules taken by mouth each week. At week eight, patients are unblinded and a follow up colonoscopy is performed. Patients who were initially randomized to placebo can go on to have FMT in the open label phase of the study.
Who is eligible to participate?
Patients with mild to moderate Crohn’s disease
Recruiting 126 patients at three Canadian centres (Edmonton, Calgary and Hamilton)
To register for this study or for more information, please contact:
Dr. Dina Kao: email@example.com
Dr. Gina Vavek: firstname.lastname@example.org
Dr. Humberto Jijon: Humberto.email@example.com
Gurmeet Bindra: firstname.lastname@example.org
Phone: 403-210-7013 or 403-399-9790
Melanie Wolfe: email@example.com
- Inflammatory Bowel Disease and Quality of Life
The Queen’s University Health Psychology research team is seeking individuals diagnosed with inflammatory bowel disease (IBD) to participate in an ethically cleared online study examining how both positive and negative variables may impact your quality of life. The study involves completing an online survey, and if you consent, it can be followed by two repeats of the survey one month apart (this is important to look at how things may change over time for you). You would complete all surveys over the course of eight weeks.
Who is eligible?
Must be at least 18 years of age and fluent in English.
To learn more about this study or to participate, please visit Queen's University Pain Lab
- Mindfulness and Quality of Life with IBD
Are you an adult living with Inflammatory Bowel Disease (IBD)
? If so, you are eligible to participate in a research study through the University of Saskatchewan. This study looks at psychological traits, like mindfulness (present-moment awareness), that might be associated with quality of life when living with IBD. Participants would complete a confidential and anonymous online survey (10-20 minutes),
which asks questions about IBD symptoms and psychological characteristics.
If you are interested in participating, please go to the following website: https://www.surveymonkey.ca/r/IBD
This research will help inform psychological interventions for IBD. This study has been approved by the Research Ethics Office at the University of Saskatchewan.
Researchers: Gillian Potter, Graduate Student, Psychology Department, University of Saskatchewan, firstname.lastname@example.org
Supervisor/Primary Investigator: Dr. Paulette Hunter, Associate Professor, Psychology Department, University of Saskatchewan, (306) 966-2175, email@example.com
Studies listed here have been submitted to Crohn’s and Colitis Canada by researchers and their teams. This means this list does not include all studies happening related to Crohn’s disease and ulcerative colitis. Below you will find two other websites that list more studies that people with Crohn’s and colitis in Canada may be eligible to participate in.
You may search for clinical trials through the following sites:
Crohn’s and Colitis Canada is an independent, voluntary health agency and does not approve, endorse or recommend any specific product or therapy but provides information to assist individuals in making their own decisions.